EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MAY 8, 2019
Media advisory: To contact corresponding author Pooja A. Lagisetty, M.D., M.Sc., email Kara Gavin at firstname.lastname@example.org. The full study is linked to this news release.
Embed this link to provide your readers free access to the full-text article: This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2732871?guestAccessKey=85d2749b-f483-45ae-ad34-513cfa5584a2&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=05082019
Bottom Line: This study used national survey data to estimate buprenorphine prescription rates to treat opioid use disorder by race/ethnicity and by payment type for office visits, which is how most patients with buprenorphine prescriptions get care. Researchers report buprenorphine office visits increased from 0.04% to 0.36% of ambulatory visits from 2004-2015 and that represented about 13.4 million visits from 2012-2015. Buprenorphine prescriptions were received at more visits from 2012-2015 by white patients than patients of other races/ethnicities. Office visits were most commonly paid for by private insurance or were self-pay. Increasing rates of opioid overdoses mean it is important that policy and research efforts address racial/ethnic and payment differences in access to treatment for opioid use disorder.
Authors: Pooja A. Lagisetty, M.D., M.Sc., University of Michigan, School of Medicine, Ann Arbor, and coauthors
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email email@example.com.